Drug intelligence / Profile preview

paracetamol + propyphenazone + caffeine

Development stage
Unknown
Lead developer
Roche
Modality
Small Molecules
Administration
Oral
01

Overview

Paracetamol + propyphenazone + caffeine is an oral fixed-dose, non-opioid analgesic-antipyretic combination used for short-term treatment of headache, migraine, fever, dysmenorrhea, toothache, and other acute pain states. It combines paracetamol, a centrally acting analgesic and antipyretic; propyphenazone, a pyrazolone analgesic with cyclooxygenase-inhibitory and anti-inflammatory activity; and caffeine, an adenosine-receptor antagonist used as an analgesic adjuvant. A common Saridon tablet formulation contains paracetamol 250 mg, propyphenazone 150 mg, and caffeine 50 mg, although strengths vary among brands and markets. The exact three-component combination is documented as an analgesic and antipyretic drug combination in the peer-reviewed literature and is marketed in several countries, including as Saridon. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33221830/))

Brand names
Bodrex MigraCaffetin LightSaridonSaridon-NSariphezon
Other names
acetaminophen + caffeine + propyphenazonecaffeine + paracetamol + propyphenazoneparacetamol + caffeine + propyphenazonepropyphenazone + paracetamol + caffeinepropyphenazone/paracetamol/caffeine
02

Targets

ADORA1 (Adenosine receptor A1 subtype)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on paracetamol + propyphenazone + caffeine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + propyphenazone + caffeine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call